CJC-1295 10 mg NO DAC | NeuroPept Labs

Description

CJC-1295 No DAC also known as Modified GRF (1-29) or Mod GRF 1-29 is a synthetic, tetrasubstituted analogue of human growth hormone-releasing hormone (GHRH[1-29]) designed to resist enzymatic degradation while maintaining high-affinity binding to the GHRH receptor (GHRHR) in the anterior pituitary. Unlike its DAC-modified counterpart, CJC-1295 No DAC lacks the albumin-binding Drug Affinity Complex (DAC) modification, resulting in a pharmacokinetic profile that closely mimics the physiological, pulsatile pattern of endogenous GHRH secretion.

NeuroPept Labs supplies CJC-1295 No DAC 10mg as a research-grade lyophilized peptide intended strictly for in vitro laboratory and analytical research use. All batches are synthesised under controlled conditions and verified through third-party analytical testing. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images.

Mechanism of Action (Research Overview)

CJC-1295 No DAC retains the core GHRH(1-29) receptor binding sequence with four amino acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that confer resistance to DPP-IV-mediated cleavage and improve metabolic stability. Upon binding to GHRHR on anterior pituitary somatotrophs, it activates Gs/adenylyl cyclase signalling, increasing intracellular cAMP and triggering acute, pulsatile GH secretion.

• GHRH receptor agonism binds GHRHR with high affinity, stimulating pulsatile GH release from anterior pituitary somatotroph cells
• Pulsatile GH secretion pattern produces acute GH elevations returning to baseline within 2-3 hours, accurately mimicking the endogenous ultradian GH rhythm
• No albumin binding  absence of DAC modification means no prolonged plasma retention; ideal for acute-response and combination research protocols
• DPP-IV resistance tetrasubstitution modifications protect against rapid enzymatic degradation seen with native GHRH (~7-10 minute half-life)
• Half-life (~30 minutes) substantially extended compared to native GHRH while maintaining pulsatile pharmacokinetics

CJC-1295 No DAC is frequently studied alongside Ipamorelin a GHS-R1a ghrelin receptor agonist as complementary GHRHR and GHS-R1a activation has been shown to produce additive effects on pulsatile GH secretion in research models.

CJC-1295 No DAC vs CJC-1295 With DAC

Research Applications

• Neuroendocrine axis studies GHRHR receptor binding kinetics and acute somatotroph signalling
• Pulsatile GH secretion modelling replicating physiological ultradian GH rhythms in preclinical models
• Combination peptide research dual-pathway GHRHR + GHS-R1a stimulation studies with Ipamorelin
• IGF-1 downstream pathway research GH-stimulated hepatic IGF-1 production and anabolic signalling
• Short-duration in vitro and ex vivo experiments where compound half-life must be controlled and limited
• Structure-activity relationship studies evaluating how tetrasubstitution modifications affect GHRHR affinity and selectivity

Product Specifications

Storage and Handling

• Store lyophilized peptide at -20°C or below prior to reconstitution
• Avoid repeated freeze-thaw cycles
• Protect from direct light, humidity, and room temperature exposure
• Reconstitute using sterile laboratory solvents under aseptic conditions
• Once reconstituted, store at 4°C and use within recommended timeframes

Frequently Asked Questions

What is CJC-1295 No DAC?

CJC-1295 No DAC (also called Modified GRF 1-29) is a synthetic tetrasubstituted analogue of GHRH(1-29) that binds the GHRH receptor to stimulate pulsatile growth hormone release. Unlike CJC-1295 with DAC, it lacks albumin-binding modification, resulting in a short (~30 minute) half-life that closely mimics physiological GHRH pulsatility.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC contains a Drug Affinity Complex (DAC) modification enabling covalent albumin binding, extending its half-life to approximately 6-8 days and producing sustained basal GH elevation. CJC-1295 No DAC lacks this modification, producing acute pulsatile GH release over ~30 minutes, more closely matching endogenous GHRH pharmacokinetics.

Why is CJC-1295 No DAC used with Ipamorelin in research?

CJC-1295 No DAC activates the GHRH receptor (GHRHR), while Ipamorelin activates the ghrelin receptor (GHS-R1a). These are distinct receptor pathways within the GH axis. Research protocols combining both peptides study dual-pathway stimulation to examine additive or synergistic effects on pulsatile GH secretion and downstream IGF-1 signalling.

Scientific References

1. Prolonged Stimulation of GH and IGF-1 by CJC-1295 PubMed 2006
2. GHRH Analogs: CJC-1295 DAC vs. Non-DAC Pharmacokinetics Oath Research 2026
3. CJC-1295 With DAC vs CJC-1295 No DAC: Research Comparison Palmetto Peptides 2026

Research Use Disclaimer: All products sold by NeuroPept Labs are intended strictly for in vitro laboratory research and scientific investigation by qualified professionals. They are not approved for human consumption, medical treatment, or veterinary use. Purchasers are responsible for compliance with applicable regulations in their jurisdiction.